Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Axsome Therapeutics Inc (GB:0HKF)
LSE:0HKF
Holding GB:0HKF?
Track your performance easily
0HKF Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$55.64 - $98.17
Previous Close$82.97
Volume387.00
Average Volume (3M)316.00
Market Cap
$4.07B
Enterprise Value$3.95B
Total Cash (Recent Filing)$315.66M
Total Debt (Recent Filing)$190.60M
Price to Earnings (P/E)―
Beta0.79
Next Earnings
Nov 04, 2024EPS Estimate
-$1.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding48,000,205
10 Day Avg. Volume237
30 Day Avg. Volume316
Standard Deviation0.31
R-Squared0.06
Alpha0.05
Financial Highlights & Ratios
Price to Book (P/B)40.51
Price to Sales (P/S)13.97
Price to Cash Flow (P/CF)-33.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue13.54
Enterprise Value/Gross Profit16.14
Enterprise Value/Ebitda-13.77
Forecast
1Y Price Target
$121.31Price Target Upside46.21% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
Axsome Therapeutics News
Bulls Say, Bears Say
Bulls Say
Market OpportunityAXS-05 in AD agitation represents a significant opportunity, with the potential market valued at over $1.6B.
Product EfficacyAXS-05 has already demonstrated efficacy in two well-controlled trials, and the FDA is sensitive to the unmet need in AD agitation.
Sales PerformanceAuvelity has generated approximately $254M in sales through the initial seven quarters of its launch.
Bears Say
Clinical TrialsIf ADVANCE-2 fails, the stock could decline significantly, raising doubts about AXSM's ability to execute on its pipeline.
Financial PerformanceGrowing opex pushed EPS to the more negative end of the consensus range.
Stock ExpectationsThe stock is expected to react negatively to the below-expectations EPS and in-line sales for Auvelity.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.50% Insiders
17.95% Mutual Funds
0.02% Other Institutional Investors
68.92% Public Companies and
Individual Investors
0HKF FAQ
What was Axsome Therapeutics Inc’s price range in the past 12 months?
Axsome Therapeutics Inc lowest share price was $55.64 and its highest was $98.17 in the past 12 months.
What is Axsome Therapeutics Inc’s market cap?
Currently, no data Available
When is Axsome Therapeutics Inc’s upcoming earnings report date?
Axsome Therapeutics Inc’s upcoming earnings report date is Nov 04, 2024 which is in 24 days.
How were Axsome Therapeutics Inc’s earnings last quarter?
Axsome Therapeutics Inc released its earnings results on Aug 05, 2024. The company reported -$1.67 earnings per share for the quarter, missing the consensus estimate of -$1.307 by -$0.363.
Is Axsome Therapeutics Inc overvalued?
According to Wall Street analysts Axsome Therapeutics Inc’s price is currently Undervalued.
Does Axsome Therapeutics Inc pay dividends?
Axsome Therapeutics Inc does not currently pay dividends.
What is Axsome Therapeutics Inc’s EPS estimate?
Axsome Therapeutics Inc’s EPS estimate is -$1.35.
How many shares outstanding does Axsome Therapeutics Inc have?
Axsome Therapeutics Inc has 48,000,206 shares outstanding.
What happened to Axsome Therapeutics Inc’s price movement after its last earnings report?
Axsome Therapeutics Inc reported an EPS of -$1.67 in its last earnings report, missing expectations of -$1.307. Following the earnings report the stock price went down -4.074%.
Which hedge fund is a major shareholder of Axsome Therapeutics Inc?
Among the largest hedge funds holding Axsome Therapeutics Inc’s share is Fairmount Funds Management Llc. It holds Axsome Therapeutics Inc’s shares valued at 190M.
---
Axsome Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$121.31 (46.21% Upside)
$121.31 (46.21% Upside)
Blogger Sentiment
Bullish
GB:0HKF Sentiment 100%
Sector Average 70%
Sector Average 70%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
18.69%
12-Months-Change
Fundamentals
Return on Equity
-161.69%
Trailing 12-Months
Asset Growth
-10.37%
Trailing 12-Months
Company Description
Axsome Therapeutics Inc
Axsome Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies for the management of central nervous system disorders. Its product candidates include AXS-02 and AXS-06 which are developing for multiple indications. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.
---
0HKF Earnings Call
Q2 2024
0:00 / 0:00
---
0HKF Stock 12 Month Forecast
Average Price Target
$121.31
▲(46.21% Upside)
Technical Analysis
Axsome Therapeutics
―
Annovis Bio
―
Bioxcel Therapeutics
―
SAGE Therapeutics
―
Cytokinetics
―
Best Analysts Covering 0HKF
1 Year
1 Year Success Rate
13/16 ratings generated profit
1 Year Average Return
+45.77%
assigned a buy rating 2 months ago
Copying Joon Lee's trades and holding each position for 1 Year would result in 81.25% of your transactions generating a profit, with an average return of +45.77% per trade.
---